Goldman Sachs Group Inc. Lowers Position in PMV Pharmaceuticals, Inc. $PMVP

Goldman Sachs Group Inc. decreased its holdings in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) by 25.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 90,263 shares of the company’s stock after selling 30,982 shares during the period. Goldman Sachs Group Inc. owned about 0.17% of PMV Pharmaceuticals worth $98,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Northern Trust Corp lifted its position in shares of PMV Pharmaceuticals by 23.2% during the 4th quarter. Northern Trust Corp now owns 107,340 shares of the company’s stock valued at $162,000 after buying an additional 20,190 shares in the last quarter. Aldebaran Capital LLC lifted its position in shares of PMV Pharmaceuticals by 4.3% during the 1st quarter. Aldebaran Capital LLC now owns 523,553 shares of the company’s stock valued at $571,000 after buying an additional 21,363 shares in the last quarter. Two Sigma Investments LP lifted its position in shares of PMV Pharmaceuticals by 5.0% during the 4th quarter. Two Sigma Investments LP now owns 506,986 shares of the company’s stock valued at $766,000 after buying an additional 23,931 shares in the last quarter. Squarepoint Ops LLC lifted its position in shares of PMV Pharmaceuticals by 68.7% during the 4th quarter. Squarepoint Ops LLC now owns 73,015 shares of the company’s stock valued at $110,000 after buying an additional 29,722 shares in the last quarter. Finally, Peapod Lane Capital LLC lifted its position in shares of PMV Pharmaceuticals by 9.8% during the 1st quarter. Peapod Lane Capital LLC now owns 489,370 shares of the company’s stock valued at $533,000 after buying an additional 43,626 shares in the last quarter. Hedge funds and other institutional investors own 90.20% of the company’s stock.

Insider Buying and Selling

In related news, major shareholder Orbimed Advisors Llc sold 500,000 shares of the stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $1.80, for a total value of $900,000.00. Following the completion of the transaction, the insider directly owned 5,975,291 shares of the company’s stock, valued at approximately $10,755,523.80. This represents a 7.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 7.60% of the company’s stock.

PMV Pharmaceuticals Price Performance

Shares of NASDAQ:PMVP opened at $1.40 on Wednesday. PMV Pharmaceuticals, Inc. has a 1 year low of $0.81 and a 1 year high of $1.84. The firm has a market capitalization of $74.19 million, a price-to-earnings ratio of -0.89 and a beta of 1.52. The business’s 50 day moving average price is $1.42 and its 200-day moving average price is $1.18.

PMV Pharmaceuticals (NASDAQ:PMVP) last announced its earnings results on Thursday, August 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). On average, sell-side analysts expect that PMV Pharmaceuticals, Inc. will post -1.06 earnings per share for the current year.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.